News
FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback